Evgen Pharma PLC Appointment of Chief Executive Officer (9223Z)
September 24 2020 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 9223Z
Evgen Pharma PLC
24 September 2020
Evgen Pharma Plc
("Evgen" or "the Company")
Appointment of Chief Executive Officer
Evgen (AIM: EVG), a clinical stage drug development company
focused on the treatment of cancer and other conditions, announces
that Huw Jones PhD will be joining the Board as Chief Executive
Officer in early October.
Dr Jones has over 30 years' experience of leadership roles in
public and private R&D-based companies within the biotechnology
and pharmaceutical sector, with a particular focus on pre-clinical
and clinical drug development, dilutive and non-dilutive financing
and business development. He is Chairman of Chronos Therapeutics
Ltd, Non-Executive Director of Rexgenero Ltd and Strategic Advisor
to Gen2 Neuroscience Ltd. Dr Jones holds a PhD in pharmacology from
the University of Birmingham, UK.
Barry Clare, Chairman of Evgen commented: "The Board is
delighted to appoint Huw as our new CEO as we work together to
deliver the undoubted potential of SFX-01. We believe that SFX-01
has significant value across a range of diseases including cancer
and respiratory diseases such as COVID-19 ."
Commenting on his appointment, Huw Jones said : "I am honoured
to join the Board of Evgen at such an exciting time and to working
with Board colleagues, management and partners to realise the
promise of SFX-01. I've been impressed by the focus and commitment
of my new colleagues and look forward to working with them towards
providing a new treatment for patients with high unmet medical
needs."
The following information regarding the appointment of Dr Huw
Jones (aged 60) is required to be disclosed under Schedule 2(g) of
the AIM Rules for Companies:
Current directorships and/or partnerships
Daffodil Consulting LLP
Chronos Therapeutics Limited
Rexgenero Limited
In accordance with Schedule 2(g) v, Dr Jones was CEO of Ardana
Plc at the time of its administration in June 2008.
There are no further disclosures to be made under Schedule 2(g)
of the AIM Rules for Companies.
The information communicated in this announcement is inside
information for the purposes of Article 7 of EU Regulation
596/2014
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It is listed on
the AIM market of the London Stock Exchange and trades under the
ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFLFVEAAIVFII
(END) Dow Jones Newswires
September 24, 2020 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024